Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Baxter
AstraZeneca
Harvard Business School
McKesson

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 6,531,128

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,531,128
Title: Methods for treating glaucoma
Abstract:This invention provides a method for treating a subject with glaucoma by administrating a composition containing an agent or molecule which antagonize, inhibits, inactivates, reduce, suppresses, antagonizes, and/or limits the release, synthesis, or production from cells of TNF-.alpha. thereby treating the subject with glaucoma.
Inventor(s): Wax; Martin B. (Wildwood, MO), Tezel; Gulgun (St. Louis, MO)
Assignee: Pharmacia Corporation (St. Louis, MO)
Application Number:09/500,023
Patent Claims:1. A method for treating a subject with glaucoma comprising the steps of administrating a compound or a composition containing an agent or molecule, which antagonizes, inhibits, inactivates, reduce suppresses, and/or limits the release, synthesis, or production of TNF-.alpha., from cells in the retina, thereby treating the subject with glaucoma.

2. The method of claim 1, wherein the molecule is a recombinant TNF-.alpha. soluble receptor.

3. The method of claim 2, wherein the molecule is etanercept.

4. The method of claim 1, wherein the molecule is an anti-TNF-.alpha. antibody.

5. The method of claim 1, wherein said composition further comprises a diluent and suitable carrier.

6. The method of claim 1, wherein the compound or composition is administered ocularly, parenterally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, intravascularly,or subcutaneously, intraperitonealy, by topical drops or ointment, periocular injection, systemically by intravenous injection or orally, intracamerally into the anterior chamber or vitreous, via a depot attached to the intraocular lens implant inserted during surgery, or via a depot placed in the eye sutured in the anterior chamber or vitreous.

Details for Patent 6,531,128

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Immunex Corporation ENBREL etanercept For Injection 103795 1998-11-02 ⤷  Try it Free 2039-02-26
Immunex Corporation ENBREL etanercept For Injection 103795 1999-05-27 ⤷  Try it Free 2039-02-26
Immunex Corporation ENBREL etanercept Injection 103795 2004-09-27 ⤷  Try it Free 2039-02-26
Immunex Corporation ENBREL etanercept Injection 103795 2007-02-01 ⤷  Try it Free 2039-02-26
Immunex Corporation ENBREL MINI etanercept Injection 103795 2017-09-14 ⤷  Try it Free 2039-02-26
Immunex Corporation ENBREL etanercept Injection 103795 ⤷  Try it Free 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
McKinsey
AstraZeneca
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.